Evidence map›Paper›PMID 42041407›Full record

ReviewBiosensors2026

Point-of-Care Electrochemical Diagnostic Developments for Multidrug-Resistant Bacteria: Role of Aptamers and Nanomaterials.

Kamna Ravi, Baljit Singh

Abstract readReview
In one paragraph

Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kamna RaviMiCRA Biodiagnostics Technology Gateway, Technological University Dublin (TU Dublin), D24 FKT9 Dublin, Ireland.
Baljit SinghMiCRA Biodiagnostics Technology Gateway, Technological University Dublin (TU Dublin), D24 FKT9 Dublin, Ireland.ORCID 0000-0002-0871-883X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unchecked and uncontrolled global spread of multidrug-resistant (MDR) bacteria is a serious challenge to healthcare and modern medicine, and demands diagnostic approaches that are rapid, sensitive, multiplexed, and reliable in point-of-care (POC) settings. At the interface of nanomaterials and aptamer-based biosensing, significant advances have been reported. The convergence of portable electrochemical sensing technologies, smartphone-based readout systems, and artificial intelligence (AI)- and machine learning (ML)-based data analysis is also playing a significant role in advancing this area. This perspective reflects on the most recent breakthroughs and translational developments in electrochemical nano-aptasensors for MDR bacterial detection, covering diagnostic targets and translation trends, nanomaterials advancements, aptamer engineering-integration, POC strategies and microfluidics platforms, and novel multimodal strategies that enhance accuracy, reliability, and efficiency in POC testing. Moreover, limitations and knowledge gaps in this area, as well as key considerations for sustainable development, large-scale manufacturing, and deployment of integrated electrochemical nano-aptasensors, are also highlighted. Electrochemical nano-aptasensors can pave the way for the transformation of MDR bacterial diagnosis, but need coordinated translational efforts for POC diagnostic advancements towards real-world applications.

Indexed as

Aptamers, NucleotideBiosensing TechniquesDrug Resistance, Multiple, BacterialElectrochemical TechniquesNanostructuresPoint-of-Care SystemsBacteriaHumansAptamers, Nucleotide3D printing and smart connectivityantimicrobial resistanceantimicrobial susceptibility testingelectrochemical nano-aptasensorlab-on-a-chipmicrofluidicsmultidrug-resistant bacteriananomaterialspoint-of-careSELEX

Identifiers

PMID42041407
PMCPMC13113993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.